Novartis AG (NVS) Equity Report Q3FY24
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
NVS’s revenue has increased by 9% to $13.17bn in Q3FY24 from $12.09bn in Q3FY23, and COGS as % of sales has decreased to 25% from 26% in the same period respectively.
Novartis stock price showed a downtrend it delivered a negative return of (13%), and the stock price declined from ~$120.4 as of 29th Aug 2024 to $104 as of 27th Nov 2024.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
